BME:GRFBiotechs
Grifols (BME:GRF) Starts Phase 3 Trials As The Undervalued Case Faces A Fresh Test
Grifols (BME:GRF) stock is back in focus after the company dosed the first patients in two Phase 3 trials designed to expand U.S. labels for key immunoglobulin therapies GAMUNEX-C and XEMBIFY.
See our latest analysis for Grifols.
Despite the positive reaction around the Phase 3 trial dosing, with a 1-day share price return of 3.72% and 7-day share price return of 5.68%, Grifols’ momentum is building from a low base, as the year to date share price return is down 15.89% and the 1-year total...